Journal Article
. 2017 Oct; 3(12):e173290.
doi: 10.1001/jamaoncol.2017.3290.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ovarian Tumor Tissue Analysis (OTTA) Consortium  Ellen L Goode 1 Matthew S Block 2 Kimberly R Kalli 2 Robert A Vierkant 1 Wenqian Chen 3 Zachary C Fogarty 1 Aleksandra Gentry-Maharaj 4 Aleksandra Tołoczko 5 Alexander Hein 6 Aliecia L Bouligny 1 Allan Jensen 7 Ana Osorio 8 Andreas Hartkopf 9 Andy Ryan 4 Anita Chudecka-Głaz 10 Anthony M Magliocco 11 Arndt Hartmann 12 Audrey Y Jung 13 Bo Gao 14 Brenda Y Hernandez 15 Brooke L Fridley 16 Bryan M McCauley 1 Catherine J Kennedy 14 Chen Wang 1 Chloe Karpinskyj 4 Christiani B de Sousa 17 Daniel G Tiezzi 17 David L Wachter 12 Esther Herpel 18 Florin Andrei Taran 9 Francesmary Modugno 19 Gregg Nelson 20 Jan Lubiński 5 Janusz Menkiszak 10 Jennifer Alsop 21 Jenny Lester 22 Jesús García-Donas 23 Jill Nation 20 Jillian Hung 14 José Palacios 24 Joseph H Rothstein 25 Joseph L Kelley 19 Jurandyr M de Andrade 17 Luis Robles-Díaz 26 Maria P Intermaggio 27 Martin Widschwendter 4 Matthias W Beckmann 6 Matthias Ruebner 6 Mercedes Jimenez-Linan 28 Naveena Singh 29 Oleg Oszurek 5 Paul R Harnett 14 Peter F Rambau 3 Peter Sinn 30 Philipp Wagner 9 Prafull Ghatage 20 Raghwa Sharma 31 Robert P Edwards 19 Roberta B Ness 32 Sandra Orsulic 22 Sara Y Brucker 9 Sharon E Johnatty 33 Teri A Longacre 34 Eilber Ursula 13 Valerie McGuire 35 Weiva Sieh 25 Yanina Natanzon 1 Zheng Li 1 Alice S Whittemore 36 deFazio Anna 14 Annette Staebler 37 Beth Y Karlan 22 Blake Gilks 38 David D Bowtell 39 Estrid Høgdall 7 Francisco J Candido dos Reis 17 Helen Steed 40 Ian G Campbell 41 Jacek Gronwald 5 Javier Benítez 8 Jennifer M Koziak 42 Jenny Chang-Claude 13 Kirsten B Moysich 43 Linda E Kelemen 44 Linda S Cook 45 Marc T Goodman 46 María José García 8 Peter A Fasching 6 Stefan Kommoss 9 Suha Deen 47 Susanne K Kjaer 7 Usha Menon 4 James D Brenton 48 Paul DP Pharoah 21 Georgia Chenevix-Trench 33 David G Huntsman 49 Stacey J Winham 1 Martin Köbel 3 Susan J Ramus 27 
  • PMID: 29049607
  •     53 References
  •     104 citations


Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.

Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer.

Design, Setting, And Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.

Exposures: Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.

Main Outcomes And Measures: Overall survival time.

Results: The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form.

Conclusions And Relevance: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, +9 authors, George Coukos.
N Engl J Med, 2003 Jan 17; 348(3). PMID: 12529460
Highly Cited.
Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.
David R Kroeger, Katy Milne, Brad H Nelson.
Clin Cancer Res, 2016 Jan 15; 22(12). PMID: 26763251
Highly Cited.
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Gottfried E Konecny, Chen Wang, +14 authors, Ellen L Goode.
J Natl Cancer Inst, 2014 Oct 02; 106(10). PMID: 25269487    Free PMC article.
Highly Cited.
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
Martin Köbel, Steve E Kalloger, +25 authors, Ovarian Tumor Tissue Analysis consortium.
Cancer Epidemiol Biomarkers Prev, 2013 Jul 25; 22(10). PMID: 23880734    Free PMC article.
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
S J L Mesnage, A Auguste, +13 authors, A F Leary.
Ann Oncol, 2016 Nov 20; 28(3). PMID: 27864219
Pathways of antigen processing.
Janice S Blum, Pamela A Wearsch, Peter Cresswell.
Annu Rev Immunol, 2013 Jan 10; 31. PMID: 23298205    Free PMC article.
Highly Cited. Review.
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Claudia C Preston, Matthew J Maurer, +5 authors, Keith L Knutson.
PLoS One, 2013 Nov 19; 8(11). PMID: 24244610    Free PMC article.
Highly Cited.
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, +18 authors, Ikuo Konishi.
J Clin Oncol, 2015 Sep 10; 33(34). PMID: 26351349
Highly Cited.
REporting recommendations for tumour MARKer prognostic studies (REMARK).
L M McShane, D G Altman, +4 authors, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
Br J Cancer, 2005 Aug 18; 93(4). PMID: 16106245    Free PMC article.
Highly Cited.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Peter F Rambau, Máire A Duggan, +5 authors, Martin Köbel.
Histopathology, 2016 Jan 23; 69(2). PMID: 26799366
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Francisco J Candido-dos-Reis, Honglin Song, +59 authors, Australian Ovarian Cancer Study Group.
Clin Cancer Res, 2014 Nov 16; 21(3). PMID: 25398451    Free PMC article.
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
Roel G W Verhaak, Pablo Tamayo, +39 authors, Cancer Genome Atlas Research Network.
J Clin Invest, 2012 Dec 22; 123(1). PMID: 23257362    Free PMC article.
Highly Cited.
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Jacek P Grabowski, Philipp Harter, +8 authors, Andreas du Bois.
Gynecol Oncol, 2016 Jan 26; 140(3). PMID: 26807488
Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2017 Jan 06; 67(1). PMID: 28055103
Highly Cited.
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
Liz Y Han, Mavis S Fletcher, +12 authors, Anil K Sood.
Clin Cancer Res, 2008 Jun 04; 14(11). PMID: 18519766    Free PMC article.
Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Ailsa J Oswald, Charlie Gourley.
Curr Opin Oncol, 2015 Aug 05; 27(5). PMID: 26241347
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
Michael J Callahan, Zoltan Nagymanyoki, +9 authors, Samuel C Mok.
Clin Cancer Res, 2008 Dec 03; 14(23). PMID: 19047092    Free PMC article.
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Catherine M Phelan, Karoline B Kuchenbaecker, +417 authors, Paul D P Pharoah.
Nat Genet, 2017 Mar 28; 49(5). PMID: 28346442    Free PMC article.
Highly Cited.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, +33 authors, Charles Swanton.
Science, 2016 Mar 05; 351(6280). PMID: 26940869    Free PMC article.
Highly Cited.
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.
Martin Köbel, Kurosh Rahimi, +18 authors, Anne-Marie Mes Masson.
Int J Gynecol Pathol, 2016 Mar 15; 35(5). PMID: 26974996    Free PMC article.
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
M Köbel, J Madore, +60 authors, L E Kelemen.
Br J Cancer, 2014 Oct 29; 111(12). PMID: 25349970    Free PMC article.
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.
Jan Budczies, Frederick Klauschen, +4 authors, Carsten Denkert.
PLoS One, 2012 Dec 20; 7(12). PMID: 23251644    Free PMC article.
Highly Cited.
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, +17 authors, NCIC Clinical Trials Group.
N Engl J Med, 2010 Sep 08; 363(10). PMID: 20818904
Highly Cited.
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Catherine Emmanuel, Yoke-Eng Chiew, +24 authors, Australian Ovarian Cancer Study (AOCS).
Clin Cancer Res, 2014 Oct 16; 20(24). PMID: 25316818
Cancer classification using the Immunoscore: a worldwide task force.
Jérôme Galon, Franck Pagès, +61 authors, Bernard A Fox.
J Transl Med, 2012 Oct 05; 10. PMID: 23034130    Free PMC article.
Highly Cited. Review.
Ovarian cancer epidemiology in the era of collaborative team science.
Rikki A Cannioto, Britton Trabert, Elizabeth M Poole, Joellen M Schildkraut.
Cancer Causes Control, 2017 Mar 12; 28(5). PMID: 28283879    Free PMC article.
Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.
Alexander Melamed, Emily M Hinchcliff, +6 authors, J Alejandro Rauh-Hain.
Gynecol Oncol, 2016 Oct 25; 143(2). PMID: 27612977
Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.
Siddhartha P Kar, Andrew Berchuck, +7 authors, Paul D P Pharoah.
Cancer Epidemiol Biomarkers Prev, 2017 Jun 16; 27(4). PMID: 28615364
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Blaise Clarke, Anna V Tinker, +10 authors, C Blake Gilks.
Mod Pathol, 2008 Dec 09; 22(3). PMID: 19060844
Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.
Martin Köbel, Julia Bak, +9 authors, Joseph W Carlson.
Histopathology, 2013 Dec 18; 64(7). PMID: 24329781
Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Preetha Ramalingam.
Oncology (Williston Park), 2016 Feb 20; 30(2). PMID: 26892153
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Martin Köbel, Steve E Kalloger, +13 authors, David Huntsman.
PLoS Med, 2008 Dec 05; 5(12). PMID: 19053170    Free PMC article.
Highly Cited.
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, +9 authors, Panagiotis A Konstantinopoulos.
Oncotarget, 2016 Feb 13; 7(12). PMID: 26871470    Free PMC article.
Highly Cited.
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum.
Mary Kay Washington, Jordan Berlin, +11 authors, Members of the Cancer Committee, College of American Pathologists.
Arch Pathol Lab Med, 2009 Oct 02; 133(10). PMID: 19792043    Free PMC article.
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, +75 authors, Cancer Genome Atlas Research Network.
JAMA, 2012 Jan 26; 307(4). PMID: 22274685    Free PMC article.
Highly Cited.
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, +2 authors, George Coukos.
Gynecol Oncol, 2011 Nov 02; 124(2). PMID: 22040834    Free PMC article.
Highly Cited.
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Weiva Sieh, Martin Köbel, +64 authors, Susan J Ramus.
Lancet Oncol, 2013 Jul 13; 14(9). PMID: 23845225    Free PMC article.
Highly Cited.
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Carsten Denkert, Stephan Wienert, +41 authors, Roberto Salgado.
Mod Pathol, 2016 Jul 02; 29(10). PMID: 27363491
Highly Cited.
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, +16 authors, David D L Bowtell.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698038
Highly Cited.
Integrated genomic characterization of endometrial carcinoma.
Cancer Genome Atlas Research Network, Cyriac Kandoth, +16 authors, Douglas A Levine.
Nature, 2013 May 03; 497(7447). PMID: 23636398    Free PMC article.
Highly Cited.
Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method.
A I Hida, Y Ohi.
Ann Oncol, 2015 Sep 09; 26(11). PMID: 26347098
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Seiji Mabuchi, Toru Sugiyama, Tadashi Kimura.
J Gynecol Oncol, 2016 Apr 01; 27(3). PMID: 27029752    Free PMC article.
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, +15 authors, Kunle Odunsi.
Proc Natl Acad Sci U S A, 2005 Dec 14; 102(51). PMID: 16344461    Free PMC article.
Highly Cited.
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Markéta Tomsová, Bohuslav Melichar, Iva Sedláková, Ivo Steiner.
Gynecol Oncol, 2007 Nov 27; 108(2). PMID: 18037158
Survival in women with grade 1 serous ovarian carcinoma.
Amanda Nickles Fader, James Java, +5 authors, Gynecologic Oncology Group (GOG)*.
Obstet Gynecol, 2013 Aug 24; 122(2 Pt 1). PMID: 23969788    Free PMC article.
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Chaoyang Sun, Na Li, +4 authors, Ding Ma.
PLoS One, 2014 May 03; 9(5). PMID: 24788697    Free PMC article.
Systematic Review.
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, +13 authors, Christos Sotiriou.
J Clin Oncol, 2013 Jan 24; 31(7). PMID: 23341518
Highly Cited.
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
D Scott McMeekin, David L Tritchler, +16 authors, Paul J Goodfellow.
J Clin Oncol, 2016 Jun 22; 34(25). PMID: 27325856    Free PMC article.
Endometriosis-associated ovarian cancer: a review of pathogenesis.
Michael J Worley, William R Welch, Ross S Berkowitz, Shu-Wing Ng.
Int J Mol Sci, 2013 Mar 08; 14(3). PMID: 23466883    Free PMC article.
Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma.
Linda E Kelemen, Martin Köbel.
Lancet Oncol, 2011 May 28; 12(11). PMID: 21616717
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
R J Kurman.
Ann Oncol, 2013 Dec 07; 24 Suppl 10. PMID: 24265397
Highly Cited. Review.
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.
Ugo Testa, Eleonora Petrucci, +2 authors, Elvira Pelosi.
Medicines (Basel), 2018 Feb 02; 5(1). PMID: 29389895    Free PMC article.
Highly Cited. Review.
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Mandy Stanske, Stephan Wienert, +16 authors, Silvia Darb-Esfahani.
Neoplasia, 2018 Feb 22; 20(3). PMID: 29466768    Free PMC article.
Major clinical research advances in gynecologic cancer in 2017.
Dong Hoon Suh, Miseon Kim, +4 authors, Jae Weon Kim.
J Gynecol Oncol, 2018 Feb 23; 29(2). PMID: 29468855    Free PMC article.
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Matthew S Block, Robert A Vierkant, +80 authors, Ellen L Goode.
Mayo Clin Proc, 2018 Mar 06; 93(3). PMID: 29502561    Free PMC article.
Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Paul Mayor, Kristen Starbuck, Emese Zsiros.
Gynecol Oncol, 2018 May 29; 150(2). PMID: 29803316    Free PMC article.
T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.
Drew C Deniger, Anna Pasetto, +11 authors, Steven A Rosenberg.
Clin Cancer Res, 2018 Jun 02; 24(22). PMID: 29853601    Free PMC article.
Highly Cited.
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
Ying Dai, Chengdu Sun, +2 authors, Bo Zhu.
J Cell Mol Med, 2018 Jun 02;. PMID: 29855141    Free PMC article.
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
Peter F Rambau, Robert A Vierkant, +94 authors, Martin Köbel.
J Pathol Clin Res, 2018 Aug 01; 4(4). PMID: 30062862    Free PMC article.
Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities.
Alia Ghoneum, Hesham Afify, +2 authors, Neveen Said.
Cancer Med, 2018 Aug 23; 7(10). PMID: 30133163    Free PMC article.
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.
Maureen L Drakes, Patrick J Stiff.
Cancers (Basel), 2018 Sep 12; 10(9). PMID: 30200478    Free PMC article.
The DNA damage response in immunotherapy and radiation.
Robert M Samstein, Nadeem Riaz.
Adv Radiat Oncol, 2018 Oct 30; 3(4). PMID: 30370352    Free PMC article.
Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.
Douglas J Hartman, Fahad Ahmad, +2 authors, Liron Pantanowitz.
Oral Oncol, 2018 Nov 10; 86. PMID: 30409313    Free PMC article.
Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.
Elena Fountzilas, Vassiliki Kotoula, +18 authors, George Fountzilas.
Oncotarget, 2018 Nov 28; 9(86). PMID: 30479693    Free PMC article.
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.
Katharina Dötzer, Friederike Schlüter, +10 authors, Barbara Mayer.
Cancers (Basel), 2019 Aug 29; 11(9). PMID: 31455033    Free PMC article.
Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.
Olivia D Lara, Santhoshi Krishnan, +14 authors, Anil K Sood.
Sci Rep, 2019 Nov 28; 9(1). PMID: 31772388    Free PMC article.
Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
Rong Liu, Rong Hu, +2 authors, Hong-Hao Zhou.
EBioMedicine, 2020 Jan 09; 51. PMID: 31911269    Free PMC article.
A multiomics comparison between endometrial cancer and serous ovarian cancer.
Hui Zhong, Huiyu Chen, +2 authors, Zhihui Wu.
PeerJ, 2020 Jan 17; 8. PMID: 31942259    Free PMC article.
Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis.
Xin-Lin He, Ying Zhou, +2 authors, Zhi Wang.
Sci Rep, 2020 Feb 16; 10(1). PMID: 32060343    Free PMC article.
Systematic Review.
Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations.
Masashi Fujita, Rui Yamaguchi, +18 authors, Hidewaki Nakagawa.
EBioMedicine, 2020 Mar 01; 53. PMID: 32113157    Free PMC article.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, +16 authors, J Carl Barrett.
Br J Cancer, 2018 Oct 26; 119(11). PMID: 30353044    Free PMC article.
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.
A Pawłowska, D Suszczyk, +3 authors, I Wertel.
Clin Exp Immunol, 2018 Dec 26; 195(3). PMID: 30582756    Free PMC article.
Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
Li Jiang, Xuhong Fang, +2 authors, Xipeng Wang.
Front Immunol, 2019 Jan 09; 9. PMID: 30619288    Free PMC article.
Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses.
Sue D Xiang, Kirsty L Wilson, +2 authors, Magdalena Plebanski.
Front Immunol, 2019 Jan 12; 9. PMID: 30631324    Free PMC article.
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, +14 authors, James L Gulley.
JAMA Oncol, 2019 Jan 25; 5(3). PMID: 30676622    Free PMC article.
Highly Cited.
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
Christopher B Morse, Mirna N Toukatly, +7 authors, Elizabeth M Swisher.
Gynecol Oncol, 2019 Feb 26; 153(2). PMID: 30803719    Free PMC article.
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Martin Gore, Allan Hackshaw, +19 authors, David M Gershenson.
Gynecol Oncol, 2019 Apr 22; 153(3). PMID: 31005287    Free PMC article.
Effect of an Integrated Payment System on the Direct Economic Burden and Readmission of Rural Cerebral Infarction Inpatients: Evidence from Anhui, China.
Haomiao Li, Yingchun Chen, +7 authors, Zhifang Chen.
Int J Environ Res Public Health, 2019 May 07; 16(9). PMID: 31058801    Free PMC article.
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer.
Muzamil Yaqub Want, Anna Konstorum, +7 authors, Sebastiano Battaglia.
Oncoimmunology, 2019 May 10; 8(6). PMID: 31069153    Free PMC article.
Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy.
Monika Bilska, Anna Pawłowska, +4 authors, Iwona Wertel.
J Oncol, 2020 Mar 10; 2020. PMID: 32148497    Free PMC article.
RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
Wendell D Jones, Chad M Michener, +4 authors, Ram N Ganapathi.
Cancers (Basel), 2020 Mar 12; 12(3). PMID: 32156016    Free PMC article.
Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods.
Nuzhat Ahmed, Elif Kadife, +3 authors, George Kannourakis.
Cells, 2020 Mar 19; 9(3). PMID: 32183385    Free PMC article.
The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy.
Danyang Zhou, Ying Wu, +3 authors, Tao Zhang.
J Cancer, 2020 May 06; 11(14). PMID: 32368303    Free PMC article.
Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
Yue Gao, Lingxi Chen, +5 authors, Qinglei Gao.
Oncoimmunology, 2020 May 12; 9(1). PMID: 32391193    Free PMC article.
RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy.
Ekaterina A Zhigalova, Anna I Izosimova, +7 authors, George V Sharonov.
Front Oncol, 2020 May 16; 10. PMID: 32411589    Free PMC article.
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
Anne Montfort, Stephanie Owen, +8 authors, James D Brenton.
Br J Cancer, 2020 Apr 07; 122(12). PMID: 32249277    Free PMC article.
Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy.
Jon Røikjær Henriksen, Line Nederby, +4 authors, Karina Dahl Steffensen.
J Ovarian Res, 2020 May 18; 13(1). PMID: 32414391    Free PMC article.
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation.
Julie Terzic, Amanda Seipel, +4 authors, S Intidhar Labidi-Galy.
Gynecol Oncol Rep, 2020 Jul 03; 33. PMID: 32613071    Free PMC article.
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Takemasa Tsuji, Kevin H Eng, +13 authors, Kunle Odunsi.
Oncotarget, 2020 Jul 18; 11(27). PMID: 32676168    Free PMC article.
Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer.
Anqi Wu, Sai Zhang, +4 authors, Gang Yin.
Front Genet, 2020 Aug 09; 11. PMID: 32765584    Free PMC article.
Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma.
Kyriakos Chatzopoulos, Vassiliki Kotoula, +7 authors, Georgios Fountzilas.
Head Neck Pathol, 2019 Nov 22; 14(3). PMID: 31749124    Free PMC article.
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.
Emelie Foord, Charlotte Klynning, +13 authors, Michael Uhlin.
J Immunol Res, 2020 Aug 25; 2020. PMID: 32832572    Free PMC article.
Prognostic gene expression signature for high-grade serous ovarian cancer.
J Millstein, T Budden, +122 authors, S J Ramus.
Ann Oncol, 2020 May 31; 31(9). PMID: 32473302    Free PMC article.
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
Filipe Correia Martins, Dominique-Laurent Couturier, +94 authors, James D Brenton.
Br J Cancer, 2020 Jun 20; 123(5). PMID: 32555365    Free PMC article.
Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer.
Emelie Rådestad, Charlotte Klynning, +4 authors, Michael Uhlin.
Oncoimmunology, 2019 Feb 05; 8(2). PMID: 30713791    Free PMC article.
The Role of Intra-Tumoral Heterogeneity and Its Clinical Relevance in Epithelial Ovarian Cancer Recurrence and Metastasis.
Cai M Roberts, Carlos Cardenas, Roslyn Tedja.
Cancers (Basel), 2019 Aug 02; 11(8). PMID: 31366178    Free PMC article.
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course.
Jung-Min Lee, Dana-Adriana Botesteanu, +9 authors, Jane B Trepel.
Oncol Lett, 2019 Sep 14; 18(4). PMID: 31516602    Free PMC article.
Three Genes Predict Prognosis in Microenvironment of Ovarian Cancer.
Ya Guo, Ya Li Wang, +3 authors, Heng Luo.
Front Genet, 2020 Sep 29; 11. PMID: 32983229    Free PMC article.
Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
Elena García-Martínez, Andres Redondo, +2 authors, Antonio Casado.
Angiogenesis, 2020 Jul 22; 23(4). PMID: 32691290    Free PMC article.
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients.
Matthew S Block, Allan B Dietz, +20 authors, Martin J Cannon.
Nat Commun, 2020 Oct 16; 11(1). PMID: 33057068    Free PMC article.
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Aline Talhouk, Joshy George, +122 authors, Michael S Anglesio.
Clin Cancer Res, 2020 Jun 20; 26(20). PMID: 32554541    Free PMC article.
MiRNA505/NET1 Axis Acts as a CD8+ T-TIL Regulator in Non-Small Cell Lung Cancer.
Pengyuan Zhu, Zhenchuan Liu, +2 authors, Yongxin Zhou.
Onco Targets Ther, 2020 Oct 17; 13. PMID: 33061457    Free PMC article.
Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Angela My Chan, Emeka Enwere, +16 authors, Martin Köbel.
J Pathol Clin Res, 2020 May 12; 6(4). PMID: 32391646    Free PMC article.
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.
Anne M Macpherson, Simon C Barry, Carmela Ricciardelli, Martin K Oehler.
J Clin Med, 2020 Sep 18; 9(9). PMID: 32937961    Free PMC article.
Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL).
Chiara Napoletano, Catharina Steentoff, +13 authors, Aurelia Rughetti.
Cancers (Basel), 2020 Oct 07; 12(10). PMID: 33019700    Free PMC article.
Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma.
Akira Yabuno, Hirokazu Matsushita, +8 authors, Kosei Hasegawa.
Sci Rep, 2020 Oct 30; 10(1). PMID: 33116254    Free PMC article.
A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Pietro Lo Riso, Carlo Emanuele Villa, +19 authors, Giuseppe Testa.
Genome Med, 2020 Oct 31; 12(1). PMID: 33121525    Free PMC article.
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.
Mélanie Desbois, Akshata R Udyavar, +16 authors, Yulei Wang.
Nat Commun, 2020 Nov 06; 11(1). PMID: 33149148    Free PMC article.
MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8+ T lymphocytes in human diffuse large B cell lymphoma.
Yangyang Xu, Zhenchuan Liu, +4 authors, Aibin Liang.
J Exp Clin Cancer Res, 2020 Nov 11; 39(1). PMID: 33168024    Free PMC article.
Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis.
Jiatao Hao, Hui Yu, +2 authors, Yan Xue.
Ther Adv Med Oncol, 2020 Nov 17; 12. PMID: 33193829    Free PMC article.
Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
Ignacio Romero, Susanna Leskelä, +2 authors, José Palacios.
EJC Suppl, 2020 Nov 27; 15. PMID: 33240438    Free PMC article.
The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation.
V Heredia-Soto, J A López-Guerrero, A Redondo, M Mendiola.
EJC Suppl, 2020 Nov 27; 15. PMID: 33240442    Free PMC article.
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs.
Maureen L Drakes, Cheryl M Czerlanis, Patrick J Stiff.
Cancers (Basel), 2020 Nov 14; 12(11). PMID: 33182298    Free PMC article.
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Tsung-Wei Chen, Kevin Chih-Yang Huang, +3 authors, K S Clifford Chao.
J Cancer Res Clin Oncol, 2019 Mar 16; 145(4). PMID: 30874889
Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
Shibai Yan, Juntao Fang, +4 authors, Feng Fang.
BMC Cancer, 2020 Dec 09; 20(1). PMID: 33287740    Free PMC article.
Immunotherapy Advances for Epithelial Ovarian Cancer.
Erin G Hartnett, Julia Knight, +3 authors, Anda M Vlad.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322601    Free PMC article.
Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies.
Aleksandra Klemba, Lubomir Bodnar, +4 authors, Claudine Kieda.
Int J Mol Sci, 2020 Dec 18; 21(24). PMID: 33327450    Free PMC article.
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer.
Marie Christine Wulff Westergaard, Katy Milne, +13 authors, Inge Marie Svane.
Cancers (Basel), 2020 Dec 24; 12(12). PMID: 33352957    Free PMC article.
PD-L1 in Combination with CD8+TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma.
Zihan Zhou, Dianbin Mu, +5 authors, Man Hu.
Cancer Manag Res, 2021 Jan 01; 12. PMID: 33380831    Free PMC article.
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Vinaya Gogineni, Susan Morand, +11 authors, John Nemunaitis.
J Cancer, 2021 Jan 05; 12(1). PMID: 33391401    Free PMC article.
Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma.
Yoshiyuki Nakamura, Zhu Zhenjie, +5 authors, Yasuhiro Fujisawa.
Front Oncol, 2021 Jan 05; 10. PMID: 33392063    Free PMC article.
Systematic Review.
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
N Sobhani, G Roviello, +12 authors, D Generali.
Mol Biol Rep, 2019 Mar 07; 46(3). PMID: 30840203
Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis.
Rixin Zhang, Tiegang Li, +6 authors, Min Yang.
Front Oncol, 2021 Jan 12; 10. PMID: 33425745    Free PMC article.
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Moran Yang, Jiaqi Lu, +5 authors, Haiou Liu.
J Immunother Cancer, 2021 Jan 17; 9(1). PMID: 33452206    Free PMC article.
Current and future immunotherapy approaches in ovarian cancer.
Nazım Can Demircan, Stergios Boussios, Tolga Tasci, Mehmet Akif Öztürk.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490226    Free PMC article.
Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
Thinle Chodon, Amit A Lugade, Sebastiano Battaglia, Kunle Odunsi.
Hematol Oncol Clin North Am, 2018 Nov 06; 32(6). PMID: 30390758    Free PMC article.
Circulating CD14+ HLA-DRlo/- monocytic cells as a biomarker for epithelial ovarian cancer progression.
Ashley E Stenzel, Scott I Abrams, +19 authors, Kirsten B Moysich.
Am J Reprod Immunol, 2020 Sep 10; 85(3). PMID: 32905653    Free PMC article.
Remission-Stage Ovarian Cancer Cell Vaccine with Cowpea Mosaic Virus Adjuvant Prevents Tumor Growth.
Courtney T Stump, Gregory Ho, +5 authors, Steven Fiering.
Cancers (Basel), 2021 Feb 11; 13(4). PMID: 33562450    Free PMC article.
PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Christine Bekos, Dietmar Pils, +6 authors, Stefanie Aust.
Sci Rep, 2021 Mar 20; 11(1). PMID: 33737722    Free PMC article.
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Veronica Olivo Pimentel, Damiënne Marcus, +8 authors, Philippe Lambin.
J Immunother Cancer, 2021 Mar 11; 9(3). PMID: 33688020    Free PMC article.
The immune landscape during the tumorigenesis of cervical cancer.
Yiying Wang, Mengdi He, +4 authors, Haiou Liu.
Cancer Med, 2021 Mar 12; 10(7). PMID: 33694292    Free PMC article.
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Robert M Samstein, Chirag Krishna, +25 authors, Nadeem Riaz.
Nat Cancer, 2021 Apr 10; 1(12). PMID: 33834176    Free PMC article.
High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
Yacine Bareche, Sandra Pommey, +11 authors, John Stagg.
J Immunother Cancer, 2021 Mar 28; 9(3). PMID: 33771891    Free PMC article.
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
Tao Dao, Martin G Klatt, +8 authors, David A Scheinberg.
Cancer Immunol Immunother, 2020 Oct 31; 70(5). PMID: 33123756    Free PMC article.
Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning.
Christos G Gavriel, Neofytos Dimitriou, +5 authors, Peter D Caie.
Cancers (Basel), 2021 May 01; 13(7). PMID: 33915698    Free PMC article.
T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review.
Jessica W Y Wu, Sudiksha Dand, +4 authors, Joshua D Ooi.
Front Immunol, 2021 May 01; 12. PMID: 33927729    Free PMC article.
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Johanne I Weberpals, Trevor J Pugh, +19 authors, Harmanjatinder S Sekhon.
Cancer Med, 2021 Apr 04; 10(9). PMID: 33811746    Free PMC article.
Development and validation of an immune prognostic signature for ovarian carcinoma.
Seema Khadirnaikar, Pranjal Kumar, Sudhanshu Kumar Shukla.
Cancer Rep (Hoboken), 2020 Aug 15; 3(4). PMID: 32794637    Free PMC article.
Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer.
Xibo Zhao, Shanshan Cong, +4 authors, Guangmei Zhang.
Front Cell Dev Biol, 2021 May 11; 9. PMID: 33968933    Free PMC article.
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation.
Adaobi Amobi-McCloud, Ravikumar Muthuswamy, +12 authors, Kunle Odunsi.
Front Immunol, 2021 May 25; 12. PMID: 34025677    Free PMC article.
Identification of a Prognostic Signature for Ovarian Cancer Based on the Microenvironment Genes.
Xiao Huo, Hengzi Sun, +4 authors, Shuhong Li.
Front Genet, 2021 Jun 01; 12. PMID: 34054929    Free PMC article.
A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Laudine Communal, Noemi Roy, +4 authors, Anne-Marie Mes-Masson.
Int J Mol Sci, 2021 Jun 03; 22(10). PMID: 34070214    Free PMC article.
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Nicola S Meagher, Linyuan Wang, +79 authors, Martin Köbel.
Mod Pathol, 2019 Jun 27; 32(12). PMID: 31239549    Free PMC article.
Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer.
Ruochen Li, Heng Zhang, +15 authors, Jiejie Xu.
Cancer Immunol Immunother, 2020 Mar 23; 69(7). PMID: 32200421
Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Guodong Zhang, Qing Xu, +5 authors, Haiou Liu.
Cancer Med, 2021 May 07; 10(12). PMID: 33955198    Free PMC article.
VISTA: A Promising Target for Cancer Immunotherapy?
Marco Tagliamento, Elisa Agostinetto, +4 authors, Matteo Lambertini.
Immunotargets Ther, 2021 Jul 01; 10. PMID: 34189130    Free PMC article.
Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family.
Peipei Gao, Ting Peng, +7 authors, Peng Wu.
Front Genet, 2021 Jul 13; 12. PMID: 34249076    Free PMC article.
Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer.
Lingyun Zhang, Wenwen Sun, +2 authors, Guoxiong Xu.
Front Cell Dev Biol, 2021 Jul 30; 9. PMID: 34322485    Free PMC article.
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Alejandro Jiménez-Sánchez, Paulina Cybulska, +31 authors, Martin L Miller.
Nat Genet, 2020 Jun 03; 52(6). PMID: 32483290    Free PMC article.
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Marine Bruand, David Barras, +32 authors, George Coukos.
Cell Rep, 2021 Jul 22; 36(3). PMID: 34289354    Free PMC article.
Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Shin-Wha Lee, Ha-Young Lee, +4 authors, Yong-Man Kim.
Int J Mol Sci, 2021 Sep 11; 22(17). PMID: 34502561    Free PMC article.
Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma.
Jiatao Hao, Yumeng Cao, +3 authors, Yan Xue.
Front Genet, 2021 Sep 28; 12. PMID: 34567061    Free PMC article.
Upregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients with Ovarian Cancer.
Rui Chen, Jianhong Cao, +2 authors, Jingxin Cheng.
J Oncol, 2021 Oct 02; 2021. PMID: 34594380    Free PMC article.
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Claudia Winkler, Matthew King, +13 authors, Gabriele Zoppoli.
JCI Insight, 2021 Sep 23; 6(18). PMID: 34549724    Free PMC article.
Immunological configuration of ovarian carcinoma: features and impact on disease outcome.
Jitka Fucikova, An Coosemans, +4 authors, Radek Spisek.
J Immunother Cancer, 2021 Oct 15; 9(10). PMID: 34645669    Free PMC article.